The Third FDA-Approved Bevacizumab

Amneal is pleased to introduce ALYMSYS® (bevacizumab-maly) Injection, a vascular endothelial growth factor (VEGF) inhibitor. It is biosimilar to AVASTIN® (bevacizumab) and offers the same dosing schedule for its approved indications. Please see Full Prescribing Information for a complete list of indications and dosing schedule.

Amneal PATHways Patient Support Program

Providers and patients will be supported through the Amneal PATHways program offering services such as:
• Benefits investigation • Prior authorization support • Affordability options • Claims assistance

IMPORTANT SAFETY INFORMATION

Indications and Usage

ALYMSYS® (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

  • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
  • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • First-Line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel.
  • Recurrent glioblastoma in adults.
  • Metastatic renal cell carcinoma in combination with interferon alfa.
  • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel

Limitations of Use: ALYMSYS® is not indicated for adjuvant treatment of colon cancer.

ALYMSYS® IMPORTANT SAFETY INFORMATION includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo-fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion-related reactions.

ADVERSE REACTIONSReported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

For full prescribing information, see package insert located here.

IMPORTANT SAFETY INFORMATION

Indications and Usage

ALYMSYS® (bevacizumab-maly) in the U.S. is a vascular endothelial growth factor inhibitor indicated for the treatment of:

  • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first or second-line treatment.
  • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • First-Line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel.
  • Recurrent glioblastoma in adults.
  • Metastatic renal cell carcinoma in combination with interferon alfa.
  • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer, in combination with paclitaxel

Limitations of Use: ALYMSYS® is not indicated for adjuvant treatment of colon cancer.

ALYMSYS® IMPORTANT SAFETY INFORMATION includes warnings and precautions on severe and fatal hemorrhage; arterial and venous thromboembolic events; hypertension, hypertensive crisis, and hypertensive encephalopathy; renal injury, proteinuria, and nephrotic syndrome; posterior reversible encephalopathy syndrome; embryo-fetal toxicity; ovarian failure; congestive heart failure; gastrointestinal perforations and fistula; surgery and wound healing complications, and infusion-related reactions.

ADVERSE REACTIONSReported adverse drug reactions in patients include epistaxis, hemorrhage, hypertension, exfoliative dermatitis, proteinuria, back pain, headache, rhinitis, taste alteration, dry skin, and lacrimation disorder.

For full prescribing information, see package insert located here.

Simple jQuery Modal